30 closest matches · ranked by relevance
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
Adrenal Cortex Neoplasms
Primary: Percentage of Participants With a Partial or Complete Response — 4; 6 Percentage of participants
Adrenal Cortex Neoplasms
Primary: Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC) — 0; 0; 13; 0 Participants
Adrenocortical Carcinoma
Primary: Assessment of Clinical Benefit Due to Treatment With Sunitinib — 5 Participants
Adrenocortical Carcinoma · Peritoneal Carcinomatosis
Primary: Intraperitoneal Progression Free Survival (PFS) — 19 Months
Carcinoma, Adrenal Cortical
Primary: Overall Survival — 108; 124 participants
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Adrenal Tumors
Primary: Increase in Catecholamine
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Recurrent Adrenocortical Carcinoma · Stage III Adrenocortical Carcinoma · Stage IV Adrenocortical Carcinoma
Primary: The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response…
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Locally Advanced Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma · Metastatic Paraganglioma
Primary: Objective Response Rate — 25 percentage of participants
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
Pheochromocytoma · Paraganglioma
Primary: Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease — 28 Participants
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Neuroendocrine Tumor · Anaplastic Thyroid Cancer · Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 2; 2; 2 Participants
Endogenous Cushing's Syndrome
Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1 — 0 percentage of patients
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants